Cyclooxygenase enzymes as targets for therapeutic intervention in inflammation

Drug News and Perspectives

Volumn 13, Issue 10, 2000, Pages 587-597

  Colville Nash, P R ^a   Gilroy, D W ^a  

^a ROYAL LONDON HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

5 (4 CHLOROPHENYL) 1 (4 METHOXYPHENYL) 3 TRIFLUOROMETHYL 1H PYRAZOLE; 5 (4 FLUOROPHENYL) 1 [(4 METHYLSULFONYL)PHENYL] 3 TRIFLUOROMETHYLPYRAZOLE; 5 BROMO 2 (4 FLUOROPHENYL) 3 (4 METHYLSULFONYLPHENYL)THIOPHENE; 6 (2,4 DIFLUOROPHENYLTHIO) 5 METHANESULFONAMIDO 1 INDANONE; ANTIINFLAMMATORY AGENT; CELECOXIB; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; NIMESULIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN SYNTHASE; PROSTANOID; ROFECOXIB;

ANIMAL MODEL; CHRONIC INFLAMMATION; DIGESTIVE SYSTEM ULCER; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG MECHANISM; DRUG TARGETING; INFLAMMATION; NONHUMAN; PROTEIN EXPRESSION; REVIEW;

EID: 0034466890     PISSN: 02140934     EISSN: None     Source Type: Journal    
DOI: 10.1358/dnp.2000.13.10.661378     Document Type: Review

References (69)

1. The prostaglandins
2. Microcirculatory studies with PGE1
3. Role of prostaglandin-mediated vasodilatation in inflammation
4. Prostaglandins, aspirin-like drugs and analgesia
5. A possible role for PGE1 as a modulator for temperature regulation in the central nervous system of the cat
6. Prostaglandin suppression of mitogen-stimulated lymphocytes in vitro. Changes with mitogen dose and preincubation
7. Suppression of human lymphocyte migration by PGE2
8. Role of prostaglandins on the regulation of macrophage proliferation and cytotoxic functions
9. Prostaglandin E2 inhibits production of Th1 lymphokines but not of Th2 lymphokines
10. Effect of non-steroidal anti-inflammatory drugs on immune function
11. Pharmacological mediators of various immunological and non-immunological inflammatory reactions produced in the pleural cavity
12. Effects of prostaglandins PGF2alpha and PGE1 on vascular permeability
13. Non-steroidal anti-inflammatory drugs and life threatening complications of peptic ulceration
14. Inhibition of prostaglandin synthesis is a mechanism of action for aspirin-like drugs
15. Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing
16. TIS10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/ cyclooxygenase homologue
17. Human cyclooxygenase-2 cDNA
18. Molecular cloning of human prostaglandin endoperoxide synthase type II and demonstration of expression in response to cytokines
19. Cyclooxygenase and nitric oxide synthase isoforms in rat carrageenan-induced pleurisy
20. Pharmacological and biochemical demonstration of a role of cyclooxygenase 2 in inflammation and pain
21. Selective inhibition of inducible cyclooxygenase 2 in vivo is anti-inflammatory and non-ulcerogenic
22. Selective induction of prostaglandin G/H synthase 1 by stem cell factor and dexamethasone in mast cells
23. Constitutive expression of prostaglandin endoperoxide G/H synthetase (PGHS)-2 but not PGHS-1 in human tracheal epithelial cells in vitro
24. COX-2, a synaptically induced enzyme, is expressed by excitatory neurons at postsynaptic sites in rat cerebral cortex
25. Towards a better aspirin
26. Anti-inflammatory and safety profile of DuP697, a novel orally effective prostaglandin synthase inhibitor
27. NS-398, a novel non-steroidal anti-inflammatory drug with potent analgesic and anti-pyretic effects, which causes minimal stomach lesions
28. Synthesis and biological evaluation of the 1.5-diarylpyrazole class of cyclooxygenase-2 inhibitors: Identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide (SC-58635, celecoxib)
29. The discovery of rofecoxib, [MK 966, Vioxx 4-(4′ methylsulfonylphenyl)-3-phenyl-2 (5H)-furanone], an orally active cyclooxygenase-2-inhibitor
30. The formation of a structure with the features of synovial lining by subcutaneous injection of air: An in vivo tissue culture system
31. Inducible isoforms of cyclooxygenase and nitric oxide synthase in inflammation
32. Distribution of cyclooxygenase isoforms in murine chronic granulomatous inflammation. Implications for future anti-inflammatory therapy
33. Temporal and spatial immunolocalisation of cytokines in murine chronic granulomatous tissue
34. Regulation and role of TIS10/PGS2
35. Transforming growth factor beta: Rapid induction of fibrosis and angiogenesis in viva and stimulation of collagen formation in vitro
36. Differential effects of inhibition of isoforms of cyclooxygenase (COX-1, COX-2) in chronic inflammation
37. In vivo cyclooxygenase expression in synovial tissues of patients with rheumatoid arthritis and osteoarthritis and rats with adjuvant and streptococcal cell wall arthritis
38. Selective inhibition of cyclooxygenase (COX)-2 reverses inflammation and expression of COX-2 and interleukin 6 in rat adjuvant arthritis
39. Models of arthritis and the search for anti-rheumatic drugs
40. Cyclooxygenase in rat pleural hypersensitivity, reactions
41. Prostaglandin modulation of mast cell-dependent inflammation
42. Possible participation of cyclooxygenase-2 in the recurrence of allergic inflammation in the rat
43. Pharmacology of a selective cyclooxygenase-2 inhibitor, L-745, 337: A novel nonsteroidal anti-inflammatory agent with an ulcerogenic-sparing effect in rat and nonhuman primate stomach
44. Rofecoxib [Vioxx, MK-0966; 4-(4′-methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone]: A potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles
45. Biochemical and pharmacological profile of a tetrasubstituted furanone as a highly selective COX-2 inhibitor
46. Cyclooxygenase 1 contributes to inflammatory responses in rats and mice: Implications for gastrointestinal toxicity
47. Pharmacological analysis of cyclooxygenase 1 in inflammation
48. Inducible cyclooxygenase may have anti-inflammatory properties
49. On the identification and biological properties of prostaglandin J2
50. 15-Deoxy-delta12,14-prostaglandin J2 is a ligand for the adipocyte determination factor PPARgamma
51. The peroxisome proliferator-activated receptors (PPARs) and their effects on lipid metabolism and adipocyte differentiation
52. The PPARalpha-leukotriene pathway to inflammation control
53. The peroxisome proliferator activated receptor gamma is a negative regulator of macrophage activation
54. PPARgamma agonists inhibit production of monocyte inflammatory cytokines
55. Inhibition of inducible nitric oxide synthase by peroxisome proliferator-activated receptor agonists: Correlation with induction of heme oxygenase 1
56. Heme oxygenase: A novel target for the modulation of the inflammatory response
57. Identification of a cis-regulatory element for delta12-prostaglandin J2-induced expression of the rat heme oxygenase gene
58. 15-Deoxy-delta 12,14-prostaglandin J2 inhibits multiple steps in the NF-kappa B signaling pathway
59. Anti-inflammatory cyclopentone prostaglandins are direct inhibitors of IkappaB kinase
60. Nuclear factor-kappaB: A pivotal transcription factor in chronic inflammatory diseases
61. NF-kappa B as a target for immunosuppressive and anti-inflammatory molecules
62. 15-Deoxy-delta(12,14)-PGJ(2) induces synoviocyte apoptosis and suppresses adjuvant-induced arthritis in rats
63. Yes, but do they still get headaches?
64. Exacerbation of inflammation-associated colonic injury in rat through inhibition of cyclooxygenase-2
65. Induction of cyclooxygenase 2 in gastric mucosal lesions and its inhibition by specific antagonist delays healing in mice
66. Role of cyclooxygenase 2 in the healing of gastric ulcers in rats
67. Effects of inhibition of prostaglandin endoperoxide synthase-2 in chronic gastrointestinal ulcer models in rats
68. Tumour necrosis factor-alpha inversely regulates prostaglandin D2 and prostaglandin E2 production in murine macrophages
69. Effect of non-steroidal anti-inflammatory drugs on the course of osteoarthritis